Fate Therapeutics, Inc.

US$1.83As of Sun 8 Nov 2026, 12:00 UTC
NASDAQ:FATEHealthcare
Country USA
PE (Fwd) •••
TSR 10Y CAGR (1.34%)
Div yield —
ROE (67.79%)
Biotechnology
Beta (5Y) 2.67
PE TTM —
TSR TTM 35.93%
Mkt cap US$219.9M
ROIC (31.20%)
SE Grade™
Value
Quality
Moat
Consensus
Reference
$2.14
16.68%
(76.83%)
Hold 9|4|5|9|7
4Q25
1Q26
2Q26
3Q26
Earnings per share$
0.03
0.03
0.03
0.03
12.44%
25.88%
32.65%
22.78%
Revenue$M
13.06
13.60
13.43
14.07
0.44%
7.59%
7.42%
13.28%
Peers (US$219.9M)
Cap (US$)
PE
221.7M
—
Capital
TTM
5Y
10Y
Leveragex
0.087
(0.919)
(0.694)
EBIT/Intx
3.309
0.276
0.221
Own earn%
(1.78)
(210.37)
(195.91)
Sh yield%
27.87
23.21
22.62
Owners
Insiders/Inst%
8.96
46.55
Short interest%
5.22
SBC / revenue%
1.36
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
20
Op margin range%
14–21
$1 testx
—
Incr. ROIC%
12